Dopaminergic Ergot Derivatives and Motor Function. Proceedings of an International Symposium Held in the Wenner–Gren Center, Stockholm, July 24–25, 1978

Content: 
Already published in this series, Page ii
Front Matter, Page iii
Copyright, Page iv
LIST OF PARTICIPANTS, Pages ix-xi
PREFACE, Page xiii, K. Fuxe, D.B. Calne
THE ANATOMY OF THE EXTRAPYRAMIDAL SYSTEM, Pages 3-22, WALLE J.H. NAUTA, VALERIE B. DOMESICK
CHEMICAL ASPECTS OF ERGOT DERIVATIVES WITH CENTRAL DOPAMINERGIC ACTIVITY, Pages 23-32, HARTMUT HAUTH
BIOCHEMICAL ANATOMY OF THE EXTRAPYRAMIDAL SYSTEM, Pages 33-43, MICHAEL J. BROWNSTEIN
PATHOPHYSIOLOGY OF MOTOR PERFORMANCE IN PARKINSON'S DISEASE, Pages 45-59, EDWARD V. EVARTS, HEIKKI T. TERÄVÄINEN, DEBORAH E. BEUCHERT, DONALD B. CALNE
DOPAMINERGIC ERGOTS: DRUGS WHICH DISCRIMINATE BETWEEN THE MULTIPLE CLASSES OF DOPAMINE RECEPTORS, Pages 61-71, JOHN W. KEBABIAN, P.R. KEBABIAN, M. MUNEMURA, D.B. CALNE
DOPAMINE RECEPTORS AND PHOSPHODIESTERASES, Pages 73-83, BERTIL B. FREDHOLM
SPECIFICITY OF AGONISTS AND ANTAGONISTS AT MODEL RECEPTORS FOR DOPAMINE AND OCTOPAMINE, Pages 85-100, DENIS N. WADE, DONALD F.H. DOUGAN
INFLUENCE OF ERGOT DERIVATIVES ON THE DIFFERENT TYPES OF DOPAMINE RECEPTORS AND ON OTHER AMINE RECEPTORS IN PRIMATE BRAIN, Pages 101-114, MAYNARD H. MAKMAN, HO SAM AHN, MYRNA ROSENFELD, LEWIS A. OPLER, JOAN HELLER BROWN, B. DVORKIN
DOPAMINE AND HUNTINGTON'S DISEASE: ASSESSMENT USING THE KAINIC ACID MODEL, Pages 115-126, ROBERT SCHWARCZ, KJELL FUXE, TOMAS HÖKFELT, KURT ANDERSSON, JOSEPH T. COYLE
NEUROPHARMACOLOGY OF ERGOT DERIVATIVES, Pages 129-140, DIETER M. LOEW, JEAN-MARIE VIGOURET, ANNE-LISE JATON
ACTIONS OF ERGOT DERIVATIVES AT DOPAMINE SYNAPSES, Pages 141-157, KJELL FUXE, ROBERT SCHWARCZ, LUIGI AGNATI, BERTIL FREDHOLM, SVEN-OVE ÖGREN, CHRISTER KÖHLER, JAN-ÅKE GUSTAFSSON
DOPAMINERGIC ERGOT DERIVATIVES: SELECTIVE AGONISTS OF A NEW CLASS OF DOPAMINE RECEPTORS?, Pages 159-171, P.F. SPANO, L. FRATTOLA, S. GOVONI, G.C. TONON, M. TRABUCCHI
ACTION OF ERGOT DOPAMINERGIC AGONISTS ON MONOAMINE SYNTHESIS IN RAT BRAIN, Pages 173-186, WOLFGANG KEHR, RUTH NEUMEISTER, RENATE ZIMMERMANN
BEHAVIOURAL EFFECTS OF ERGOT DRUGS, Pages 187-205, SVEN-OVE ÖGREN, CHRISTER KÖHLER, KJELL FUXE, K. ÄNGEBY
EFFECTS OF ERGOLINES ON DOPAMINERGIC AND SEROTONERGIC SINGLE UNIT ACTIVITY, Pages 207-221, J.R. WALTERS, M.D. BARING, J.M. LAKOSKI
DOPAMINERGIC AND SEROTONERGIC EFFECTS OF ERGOT DRUGS, Pages 223-235, ELLEN K. SILBERGELD, ROBERT E. HRUSKA, SHAWN W. KENNEDY, ROGER WEIR
PHARMACOLOGICAL EFFECTS OF LISURIDE IN RODENTS MEDIATED BY DOPAMINERGIC RECEPTORS: MECHANISM OF ACTION AND INFLUENCE OF CHRONIC TREATMENT WITH LISURIDE, Pages 237-251, REINHARD HOROWSKI, HELMUT WACHTEL
THE DOPAMINEPHILLIC PROPERTIES OF ERGOLINE DERIVATIVES, Pages 253-259, MENEK GOLDSTEIN, J.Y. LEW, J. ENGEL, S. NAKAMURA, A. BATTISTA
CLINICAL PHARMACOLOGY OF ERGOTS, Pages 263-269, LOUIS LEMBERGER, ALAN RUBIN, ROSS CRABTREE
ACTIONS OF BROMOCRIPTINE IN THE SHY – DRAGER AND STEELE – RICHARDSON – OLSZEWSKI SYNDROMES, Pages 271-283, A.C. WILLIAMS, J. NUTT, C.R. LAKE, R. PFEIFFER, P.E. TEYCHENNE, M. EBERT, D.B. CALNE
MODIFICATION OF THE “ON-OFF” EFFECT WITH BROMOCRIPTINE AND LERGOTRILE, Pages 285-295, ABRAHAM N. LIEBERMAN, MARK KUPERSMITH, GOVINDAN GOPINATHAN, ELIHU ESTEY, MENEK GOLDSTEIN
BROMOCRIPTINE COMPARED WITH LEVODOPA IN PARKINSONISM, Pages 297-301, RICHARD B. GODWIN-AUSTEN
ROLE OF BROMOCRIPTINE IN THE TREATMENT OF PARKINSONISM, Pages 303-312, STANLEY FAHN, LUCIEN J. COTE, STUART R. SNIDER, ROBERT E. BARRETT, WILLIAM P. ISGREEN
DOSE-DEPENDENT LOCOMOTOR EFFECTS OF BROMOCRIPTINE IN ANIMALS AND MAN — ARE SOME OF ITS ACTIONS DUE TO METABOLITES?, Pages 313-318, C.D. MARSDEN, P. JENNER, J.D. PARKES, P.A. PRICE, C. REAVILL
RELATIONSHIP BETWEEN BRAIN DOPAMINE TURNOVER AND THE THERAPEUTIC RESPONSE TO BROMOCRIPTINE, Pages 319-327, U.K. RINNE, R. MARTTILA, V. SONNINEN
BROMOCRIPTINE AS AN ADJUVANT TO LEVODOPA, Pages 329-335, R.C. DUVOISIN, M.R. MENDOZA, M.D. YAHR, R.D. SWEET
ERGOT DERIVATIVES WITHOUT LEVODOPA IN PARKINSONISM, Pages 337-341, GERALD STERN, ANDREW LEES, KENNETH SHAW
CLINICAL OBSERVATIONS WITH BROMOCRIPTINE IN PARKINSONISM, Pages 343-347, ULLA GRØN
ERGOT DERIVATIVES IN THE TREATMENT OF PSYCHOTIC AND HYPERKINETIC DISORDERS, Pages 349-360, CAROL A. TAMMINGA, THOMAS N. CHASE, MARTIN H. SCHAFFER
ERGOT DERIVATIVES IN DYSKINETIC AND DYSTONIC DISORDERS, Pages 361-369, MARCO TRABUCCHI, MARIAGRAZIA ALBIZZATI, PIERFRANCO SPANO, GIANCARLO TONON, LUDOVICO FRATTOLA
TOXICITY OF ERGOT ALKALOIDS, Pages 373-380, R.W. GRIFFITH
CARDIOVASCULAR EFFECTS OF ERGOT DERIVATIVES IN MAN, Pages 381-393, WALTER H. AELLIG
CARDIOVASCULAR REACTIONS TO BROMOCRIPTINE, Pages 395-403, JOHN L. REID, D. NICHOLAS BATEMAN
PSYCHIATRIC REACTION TO ERGOT DERIVATIVES, Pages 405-414, HAROLD L. KLAWANS, CAROLINE M. TANNER, CHRISTOPHER G. GOETZ
THE HEPATOTOXICITY OF ERGOT ALKALOIDS, Pages 415-429, E. ANTHONY JONES, CHARLES PLOTKIN, PAUL F. TEYCHENNE, KAMAL G. ISHAK, DONALD B. CALNE
ENDOCRINE EFFECTS OF DOPAMINERGIC ERGOT ALKALOIDS — TOXICOLOGICAL IMPLICATIONS, Pages 431-441, MICHAEL O. THORNER, WILLIAM S. EVANS, WALLACE C. NUNLEY Jr
SUBJECT INDEX, Pages 443-447